![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Biohaven Gains Experimental Drugs From Two New Pacts
Biohaven Gains Experimental Drugs From Two New Pacts
New Haven, Conn.-based Biohaven Pharmaceutical has struck a global licensing deal with Bristol Myers Squibb (BMS) to develop and market taldefgrobep alfa, an investigational therapy for treating neuromuscular diseases.
Biohaven said it plans to launch a phase 3 study this year to evaluate the drug candidate as a treatment for spinal muscular atrophy. Financial terms of the deal were not disclosed.
Biohaven also announced plans to acquire neurology drug developer Channel Biosciences, a Knopp Biosciences subsidiary, for an estimated $100 million. Under the deal, Biohaven will gain access to Channel’s lead candidate BHV-7000, an anti-seizure medication for treatment of epilepsy.
Biohaven plans to launch a clinical trial evaluating BHV-7000 for treating epilepsy this year.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct